Robust antitumor activity and low cytokine production by novel humanized anti-CD19 CAR T cells
Recent studies have described the remarkable clinical outcome of anti-CD19 chimeric
antigen receptor (CAR) T cells in treating B-cell malignancies. However, over 50% of …
antigen receptor (CAR) T cells in treating B-cell malignancies. However, over 50% of …
[HTML][HTML] Pre-clinical assessment of chimeric antigen receptor t cell therapy targeting CD19+ B cell malignancy
SI Hu, MC Ko, YH Dai, HA Lin, LC Chen… - Annals of …, 2020 - ncbi.nlm.nih.gov
Background Autologous chimeric antigen receptor (CAR) T cell therapy is a promising
therapeutic strategy for treating hematologic malignancies. A spectrum of serious …
therapeutic strategy for treating hematologic malignancies. A spectrum of serious …
Development of a novel anti-CD19 CAR containing a fully human scFv and three costimulatory domains
Y Wutti-In, J Sujjitjoon, N Sawasdee, A Panya… - Frontiers in …, 2022 - frontiersin.org
Second-generation anti-CD19-chimeric antigen receptor T cells (anti-CD19-CAR2 T cells)
are effective for treating B-cell malignancies; however, anti-CD19-CAR2 T cells can induce …
are effective for treating B-cell malignancies; however, anti-CD19-CAR2 T cells can induce …
T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts
F Nasiri, P Safarzadeh Kozani… - Frontiers in …, 2023 - frontiersin.org
Background Chimeric antigen receptor (CAR)-T cell therapy has established itself as a
potent therapeutic option for certain patients with relapsed/refractory (R/R) hematologic …
potent therapeutic option for certain patients with relapsed/refractory (R/R) hematologic …
Development of optimized cytotoxicity assays for assessing the antitumor potential of CAR-T cells
M Eugene-Norbert, A Cuffel, G Riou, L Jean… - Journal of …, 2024 - Elsevier
Abstract CAR-T cells are T cells expressing a chimeric antigen receptor (CAR) rendering
them capable of killing tumor cells after recognition of a target antigen. CD19 CAR-T cells …
them capable of killing tumor cells after recognition of a target antigen. CD19 CAR-T cells …
[HTML][HTML] Enhanced tumor immunotherapy by polyfunctional CD19-CAR T cells engineered to secrete anti-CD47 single-chain variable fragment
Y Qiu, P Liao, H Wang, J Chen, Y Hu, R Hu… - … Journal of Biological …, 2023 - ncbi.nlm.nih.gov
A high recurrence rate of non-Hodgkin's lymphoma (NHL) following chimeric antigen
receptor T (CAR T) cell treatment remains a bottleneck, and immunosuppressive tumor …
receptor T (CAR T) cell treatment remains a bottleneck, and immunosuppressive tumor …
[HTML][HTML] Chimeric antigen receptor T cells derived from CD7 nanobody exhibit robust antitumor potential against CD7-positive malignancies
D Chen, F You, S Xiang, Y Wang, Y Li… - American Journal of …, 2021 - ncbi.nlm.nih.gov
The great success of chimeric antigen receptor T (CAR-T)-cell therapy in B-cell
malignancies has significantly promoted its rapid expansion to other targets and indications …
malignancies has significantly promoted its rapid expansion to other targets and indications …
Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies
Chimeric antigen receptor (CAR)-mediated targeting of T lineage antigens for the therapy of
blood malignancies is frequently complicated by self-targeting of CAR T cells or their …
blood malignancies is frequently complicated by self-targeting of CAR T cells or their …
Functional improvement of chimeric antigen receptor through intrinsic interleukin-15Rα signaling
S Nair, JB Wang, ST Tsao, Y Liu, W Zhu… - Current Gene …, 2019 - ingentaconnect.com
Introduction: Recent studies on CD19-specific chimeric antigen receptor (CAR)-modified T
cells (CARTs) have demonstrated unprecedented successes in treating refractory and …
cells (CARTs) have demonstrated unprecedented successes in treating refractory and …
Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma
H Köksal, P Dillard, SE Josefsson… - Blood …, 2019 - ashpublications.org
T cells modified to express chimeric antigen receptor (CAR) targeting CD19 (CD19CAR)
have produced remarkable clinical responses in patients with relapsed/refractory B-cell …
have produced remarkable clinical responses in patients with relapsed/refractory B-cell …